Earlier this week, the USPTO issued three new patents (U.S. Pat. No. 11,406,781, U.S. Pat. No. 11,406,784, and U.S. Pat. No. 11,406,777) which describe a device for respiratory gas delivery through the nasal cavity and two forms of headgear to gently seal respiratory devices to a user’s skin. The new patents strengthen ResMed’s position in the medical sleep device sector. ResMed is a medical device company that develops cloud-connectable continuous positive airway pressure (CPAP) technology for users with sleep apnea and other airway obstructive sleeping disorders. These devices are then paired with ResMed’s myAir™ app so the user can track the effectiveness of CPAP therapy on their sleep cycle.

These issuances come just one week after ResMed acquired German insomnia tracking platform, Mementor, and one month after ResMed announced negotiations to acquire another German medical software company, MEDIFOX DAN. These acquisitions position ResMed to dominate the global market for in-home medical sleep device technology. With the the acquisition of MEDIFOX DAN set to close by the end of this year, expect to see a push for asset coverage of a new generation of ResMed software.